TY  - JOUR
T1  - Evaluation of ongoing mepolizumab treatment in chronic rhinosinusitis with nasal polyps
AU  - Klimek, Ludger
AU  - Förster-Ruhrmann, Ulrike
AU  - Olze, Heidi
AU  - Beule, Achim G.
AU  - Chaker, Adam M.
AU  - Hagemann, Jan
AU  - Huppertz, Tilmann
AU  - Hoffmann, Thomas K.
AU  - Dazert, Stefan
AU  - Deitmer, Thomas
AU  - Strieth, Sebastian
AU  - Wrede, Holger
AU  - Schlenter, Wolfgang
AU  - Welkoborsky, Hans-Jürgen
AU  - Wollenberg, Barbara
AU  - Becker, Sven
AU  - Bärhold, Frederike
AU  - Klimek, Felix
AU  - Casper, Ingrid
AU  - Zuberbier, Jaron
AU  - Rudack, Claudia
AU  - Cuevas, Mandy
AU  - Hintschich, Constantin A.
AU  - Guntinas-Lichius, Orlando
AU  - Stöver, Timo
AU  - Bergmann, Christoph
AU  - Werminghaus, Pascal
AU  - Pfaar, Oliver
AU  - Gosepath, Jan
AU  - Gröger, Moritz
AU  - Beutner, Caroline
AU  - Laudien, Martin
AU  - Weber, Rainer K.
AU  - Hildenbrand, Tanja
AU  - Hoffmann, Anna-Sophie
AU  - Bachert, Claus
Y1  - 2024///
JO  - Exploration of Asthma & Allergy
VL  - 2
IS  - 1
SP  - 33
EP  - 48
DO  - 10.37349/eaa.2024.00027
UR  - https://www.explorationpub.com/Journals/eaa/Article/100927
AB  - Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the mucous membranes of the nose and paranasal sinuses. Eosinophilic inflammation is described as a common endotype. The anti-interleukin-5 (IL-5) antibody mepolizumab was approved in November 2021 as an add-on therapy to intranasal glucocorticosteroids for the treatment of adults with severe CRSwNP when systemic glucocorticosteroids or surgery do not provide adequate disease control. While national and international recommendations exist for the use of mepolizumab in CRSwNP, therapy monitoring and follow-up documentation are required, and therapy discontinuation has not been adequately established yet. In this paper, recommendations for monitoring the course and efficacy of therapy as well as for reviewing the duration and possible termination of therapy are provided. For this purpose, a literature search was performed to analyze previous data on the treatment of CRSwNP with mepolizumab and to determine the available evidence by searching MEDLINE, PubMed, and the national and international trial and guideline registries and the Cochrane Library. Human studies published in the period up to and including October 2022 were considered. Based on the international literature and previous experience, recommendations for follow-up, adherence to therapy intervals and possible therapy breaks, as well as termination of therapy when using mepolizumab for the indication CRSwNP in the German health care system are given by an expert panel on the basis of a documentation sheet.
ER  -